| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $721,042 | 22 | 100 |
Sells | $0 | 0 | 0 |
| Feinberg Peter | director | 5 | $288,747 | 0 | $0 | $288,747 |
| Schall Thomas J. | director | 3 | $225,107 | 0 | $0 | $225,107 |
| Zeskind Benjamin J. | PRESIDENT AND CEO | 3 | $85,023 | 0 | $0 | $85,023 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 3 | $45,118 | 0 | $0 | $45,118 |
| Brakewood Harold Eugene | Chief Business Officer | 2 | $29,794 | 0 | $0 | $29,794 |
| HAUSMAN DIANA | director | 1 | $19,863 | 0 | $0 | $19,863 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER | 3 | $18,508 | 0 | $0 | $18,508 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | 1 | $6,967 | 0 | $0 | $6,967 |
| Morales Mallory | Chief Accounting Officer | 1 | $1,917 | 0 | $0 | $1,917 |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Over the last 12 months, insiders at Immuneering Corporation have bought $721,042 and sold $0 worth of Immuneering Corporation stock.
On average, over the past 5 years, insiders at Immuneering Corporation have bought $4.87M and sold $3.91M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Feinberg Peter (director) — $288,747. Schall Thomas J. (director) — $225,107. Zeskind Benjamin J. (PRESIDENT AND CEO) — $85,023.
The last purchase of 5,250 shares for transaction amount of $24,990 was made by Brakewood Harold Eugene (Chief Business Officer) on 2026‑01‑16.
| 2026-01-16 | Brakewood Harold Eugene | Chief Business Officer | 5,250 0.015% | $4.76 | $24,990 | +8.95% | ||
| 2026-01-15 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 2,298 0.0062% | $4.57 | $10,502 | +7.44% | ||
| 2026-01-15 | Schall Thomas J. | director | 21,645 0.06% | $4.67 | $101,041 | +7.44% | ||
| 2026-01-13 | Neufeld Leah R | CHIEF PEOPLE OFFICER | 2,626 0.0073% | $4.15 | $10,906 | +20.29% | ||
| 2026-01-12 | Feinberg Peter | director | 20,000 0.0567% | $4.35 | $86,904 | +18.01% | ||
| 2025-10-03 | Feinberg Peter | director | 7,500 0.0197% | $6.67 | $50,025 | -2.31% | ||
| 2025-10-01 | Morales Mallory | Chief Accounting Officer | 300 0.0008% | $6.39 | $1,917 | -6.29% | ||
| 2025-10-01 | Neufeld Leah R | CHIEF PEOPLE OFFICER | 800 0.002% | $6.38 | $5,103 | -6.29% | ||
| 2025-10-01 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | 1,020 0.0027% | $6.83 | $6,967 | -6.29% | ||
| 2025-09-30 | Feinberg Peter | director | 7,500 0.0208% | $7.03 | $52,730 | -14.29% | ||
| 2025-09-29 | Feinberg Peter | director | 5,000 0.0147% | $7.18 | $35,900 | -10.52% | ||
| 2025-07-02 | Zeskind Benjamin J. | PRESIDENT AND CEO | 7,015 0.0192% | $3.53 | $24,792 | +56.41% | ||
| 2025-07-02 | Neufeld Leah R | CHIEF PEOPLE OFFICER | 700 0.0019% | $3.57 | $2,499 | +56.41% | ||
| 2025-07-02 | HAUSMAN DIANA | director | 5,500 0.0154% | $3.61 | $19,863 | +56.41% | ||
| 2025-07-01 | Zeskind Benjamin J. | PRESIDENT AND CEO | 2,985 0.0081% | $3.38 | $10,087 | +63.08% | ||
| 2025-06-27 | Schall Thomas J. | director | 9,500 0.0274% | $3.66 | $34,788 | +58.64% | ||
| 2025-06-23 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 6,007 0.0166% | $2.43 | $14,596 | +127.05% | ||
| 2025-06-20 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 7,415 0.0217% | $2.70 | $20,020 | +115.82% | ||
| 2025-06-20 | Brakewood Harold Eugene | Chief Business Officer | 1,900 0.0052% | $2.53 | $4,804 | +115.82% | ||
| 2025-06-18 | Zeskind Benjamin J. | PRESIDENT AND CEO | 21,000 0.0503% | $2.39 | $50,144 | +98.92% |
| Zeskind Benjamin J. | PRESIDENT AND CEO | 2312852 6.3711% | $13M | 7 | 0 | <0.0001% |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 376496 1.0371% | $2.12M | 7 | 0 | <0.0001% |
| Feinberg Peter | director | 135441 0.3731% | $761,178.42 | 12 | 0 | <0.0001% |
| Schall Thomas J. | director | 74530 0.2053% | $418,858.60 | 4 | 0 | <0.0001% |
| Morales Mallory | Chief Accounting Officer | 27533 0.0758% | $154,735.46 | 3 | 0 | <0.0001% |
| Neufeld Leah R | CHIEF PEOPLE OFFICER | 25970 0.0715% | $145,951.40 | 4 | 0 | <0.0001% |
| Brakewood Harold Eugene | Chief Business Officer | 11050 0.0304% | $62,101.00 | 3 | 0 | <0.0001% |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | 4870 0.0134% | $27,369.40 | 3 | 0 | <0.0001% |
| HAUSMAN DIANA | director | 3000 0.0083% | $16,860.00 | 1 | 0 | |
| Cormorant Asset Management, LP | 10 percent owner | 2895273 7.9754% | $16.27M | 1 | 3 | <0.0001% |
| CARPENTER ROBERT J | director | 1148839 3.1646% | $6.46M | 1 | 0 | <0.0001% |
| BERMAN ANN E | director | 67465 0.1858% | $379,153.30 | 3 | 0 | <0.0001% |
| KEATING LAURIE | 14000 0.0386% | $78,680.00 | 2 | 0 | <0.0001% | |
| Amin Biren | CFO, TREASURER | 7898 0.0218% | $44,386.76 | 2 | 0 | <0.0001% |
| Barrett Scott | CHIEF MEDICAL OFFICER | 7563 0.0208% | $42,504.06 | 2 | 0 | <0.0001% |
$22,693,451 | 105 | 8.15% | $197.29M | |
$16,259,194 | 41 | 120.51% | $184.85M | |
Immuneering Corporation (IMRX) | $18,752,549 | 33 | -28.39% | $204.02M |
$47,292,212 | 27 | -28.21% | $177.09M | |
$167,701,902 | 27 | -3.07% | $198.66M | |
$6,915,275 | 21 | -32.61% | $220.34M | |
$38,821,584 | 20 | -2.17% | $216.98M | |
$448,999,793 | 15 | -19.99% | $182.55M | |
$135,812,721 | 14 | 17.52% | $221.09M | |
$13,259,565 | 14 | -30.38% | $222.33M | |
$1,037,470 | 13 | 78.00% | $216.52M | |
$5,905,507 | 7 | 2.69% | $226.5M | |
$99,355,998 | 7 | -65.74% | $203.53M | |
$8,286,963 | 6 | 3.09% | $217.37M | |
$299,343 | 6 | -44.75% | $189.74M | |
$272,982 | 6 | -28.53% | $227.84M | |
$20,729,984 | 5 | 51.71% | $216.49M | |
$193,101 | 3 | -25.20% | $203.37M | |
$12,750 | 2 | -39.73% | $191.15M |
| Increased Positions | 58 | +82.86% | 10M | +39.24% |
| Decreased Positions | 27 | -38.57% | 5M | -18.15% |
| New Positions | 30 | New | 4M | New |
| Sold Out Positions | 15 | Sold Out | 4M | Sold Out |
| Total Postitions | 101 | +44.29% | 32M | +21.09% |
| Fmr Llc | $58,170.00 | 13.52% | 8.79M | +9M | +3,876.04% | 2025-09-30 |
| Sanofi | $17,931.00 | 4.17% | 2.71M | +3M | New | 2025-09-30 |
| Vanguard Group Inc | $15,989.00 | 3.72% | 2.42M | +1M | +128.52% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $11,908.00 | 2.77% | 1.8M | +2M | New | 2025-09-30 |
| Exoduspoint Capital Management, Lp | $10,041.00 | 2.33% | 1.52M | +2M | New | 2025-09-30 |
| Logos Global Management Lp | $6,289.00 | 1.46% | 950,000 | +950,000 | New | 2025-09-30 |
| Citadel Advisors Llc | $6,244.00 | 1.45% | 943,144 | +943,144 | New | 2025-09-30 |
| Blackrock, Inc. | $4,509.00 | 1.05% | 681,185 | +258,427 | +61.13% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $3,641.00 | 0.85% | 550,000 | +550,000 | New | 2025-09-30 |
| Geode Capital Management, Llc | $3,400.00 | 0.79% | 513,665 | +283,390 | +123.07% | 2025-09-30 |